Apogee Therapeutics, Inc. Common Stock (APGE) Shares Outstanding 2022–TTM

Name: Apogee Therapeutics, Inc. Common Stock (APGE) shares outstanding history 2022-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-07-30

Apogee Therapeutics, Inc. Common Stock annual shares outstanding for fiscal TTM was 70 million shares, an increase of 14.8% from 61 million shares in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

APGE Annual Shares Outstanding

Shares Outstanding (annual)	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Shares Outstanding (M)	70M	61M	55M	51M	51M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

APGE Quarterly Shares Outstanding

Shares Outstanding (quarterly)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Shares Outstanding (M)	70M	61M	59M	58M	58M	55M	57M	57M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Shares Outstanding at Comparable Companies

AXSM Shares Outstanding — Axsome Therapeutics Inc
SMMT Shares Outstanding — Summit Therapeutics PLC
CYTK Shares Outstanding — Cytokinetics Inc
PRAX Shares Outstanding — Praxis Precision Medicines Inc
PTGX Shares Outstanding — Protagonist Therapeutics Inc
KRYS Shares Outstanding — Krystal Biotech Inc

More APGE metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow

All APGE financial statements → Interactive APGE charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.